Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

60 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The postmenopausal hormone replacement therapy-related breast cancer risk is decreased in women carrying the CYP2C19*17 variant.
Justenhoven C, Obazee O, Winter S, Couch FJ, Olson JE, Hall P, Hannelius U, Li J, Humphreys K, Severi G, Giles G, Southey M, Baglietto L, Fasching PA, Beckmann MW, Ekici AB, Hamann U, Baisch C, Harth V, Rabstein S, Lotz A, Pesch B, Brüning T, Ko YD, Brauch H. Justenhoven C, et al. Among authors: baisch c. Breast Cancer Res Treat. 2012 Jan;131(1):347-50. doi: 10.1007/s10549-011-1827-1. Epub 2011 Oct 26. Breast Cancer Res Treat. 2012. PMID: 22037784 No abstract available.
CYP2C19*17 is associated with decreased breast cancer risk.
Justenhoven C, Hamann U, Pierl CB, Baisch C, Harth V, Rabstein S, Spickenheuer A, Pesch B, Brüning T, Winter S, Ko YD, Brauch H. Justenhoven C, et al. Among authors: baisch c. Breast Cancer Res Treat. 2009 May;115(2):391-6. doi: 10.1007/s10549-008-0076-4. Epub 2008 Jun 3. Breast Cancer Res Treat. 2009. PMID: 18521743
A genome-wide association study to identify genetic susceptibility loci that modify ductal and lobular postmenopausal breast cancer risk associated with menopausal hormone therapy use: a two-stage design with replication.
Hein R, Flesch-Janys D, Dahmen N, Beckmann L, Lindström S, Schoof N, Czene K, Mittelstraß K, Illig T, Seibold P, Behrens S, Humphreys K, Li J, Liu J, Olson JE, Wang X, Hankinson SE, Truong T, Menegaux F, Dos Santos Silva I, Johnson N; GENICA Network; Chen ST, Yu JC, Ziogas A, Kataja V, Kosma VM, Mannermaa A, Anton-Culver H, Shen CY, Brauch H, Peto J, Guénel P, Kraft P, Couch FJ, Easton DF, Hall P, Chang-Claude J. Hein R, et al. Breast Cancer Res Treat. 2013 Apr;138(2):529-542. doi: 10.1007/s10549-013-2443-z. Epub 2013 Feb 20. Breast Cancer Res Treat. 2013. PMID: 23423446 Free PMC article.
Confirmation of the reduction of hormone replacement therapy-related breast cancer risk for carriers of the HSD17B1_937_G variant.
Obazee O, Justenhoven C, Winter S, Chang-Claude J, Rudolph A, Seibold P, Flesch-Janys D, Hannelius U, Li J, Humphreys K, Hall P, Giles G, Severi G, Baglietto L, Southey M, Rabstein S, Harth V, Lotz A, Pesch B, Brüning T, Baisch C, Ko YD, Hamann U, Brauch H. Obazee O, et al. Among authors: baisch c. Breast Cancer Res Treat. 2013 Apr;138(2):543-8. doi: 10.1007/s10549-013-2448-7. Epub 2013 Feb 21. Breast Cancer Res Treat. 2013. PMID: 23430226
Breast cancer: a candidate gene approach across the estrogen metabolic pathway.
Justenhoven C, Hamann U, Schubert F, Zapatka M, Pierl CB, Rabstein S, Selinski S, Mueller T, Ickstadt K, Gilbert M, Ko YD, Baisch C, Pesch B, Harth V, Bolt HM, Vollmert C, Illig T, Eils R, Dippon J, Brauch H. Justenhoven C, et al. Among authors: baisch c. Breast Cancer Res Treat. 2008 Mar;108(1):137-49. doi: 10.1007/s10549-007-9586-8. Epub 2007 Jun 23. Breast Cancer Res Treat. 2008. PMID: 17588204
The CYP1B1_1358_GG genotype is associated with estrogen receptor-negative breast cancer.
Justenhoven C, Pierl CB, Haas S, Fischer HP, Baisch C, Hamann U, Harth V, Pesch B, Brüning T, Vollmert C, Illig T, Dippon J, Ko YD, Brauch H. Justenhoven C, et al. Among authors: baisch c. Breast Cancer Res Treat. 2008 Sep;111(1):171-7. doi: 10.1007/s10549-007-9762-x. Epub 2007 Oct 6. Breast Cancer Res Treat. 2008. PMID: 17922187
Polymorphisms in the UBC9 and PIAS3 genes of the SUMO-conjugating system and breast cancer risk.
Dünnebier T, Bermejo JL, Haas S, Fischer HP, Pierl CB, Justenhoven C, Brauch H, Baisch C, Gilbert M, Harth V, Spickenheuer A, Rabstein S, Pesch B, Brüning T, Ko YD, Hamann U. Dünnebier T, et al. Among authors: baisch c. Breast Cancer Res Treat. 2010 May;121(1):185-94. doi: 10.1007/s10549-009-0530-y. Epub 2009 Sep 17. Breast Cancer Res Treat. 2010. PMID: 19760037
Polymorphisms of the nuclear receptor pregnane X receptor and organic anion transporter polypeptides 1A2, 1B1, 1B3, and 2B1 are not associated with breast cancer risk.
Justenhoven C, Schaeffeler E, Winter S, Baisch C, Hamann U, Harth V, Rabstein S, Spickenheuer A, Pesch B, Brüning T, Ko YD, Schwab M, Brauch H. Justenhoven C, et al. Among authors: baisch c. Breast Cancer Res Treat. 2011 Jan;125(2):563-9. doi: 10.1007/s10549-010-1046-1. Epub 2010 Jul 16. Breast Cancer Res Treat. 2011. PMID: 20635135
60 results